Home / Stocks / Bal Pharma Ltd.
BALPHARMA

Bal Pharma Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹84.61

Change

-1.39 (-1.62%)

Open

₹85.0

Prev. Close

₹86.0

Day High

₹85.0

Day Low

₹82.0

Volume Analysis

Traded

10,434

Delivered

15,101

Delivery %

59.17%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •High debt-to-equity ratio (2.07)
  • •Low return on equity (7.79%)
  • •Below-average fundamentals quality score (39/100)

Opportunities (1)

  • •Strong 3-year EPS growth (33.9%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹88.74 ₹86.87 ₹85.74 ₹83.87 ₹82.74 ₹80.87 ₹79.74
Fibonacci ₹86.87 ₹85.72 ₹85.02 ₹83.87 ₹82.72 ₹82.02 ₹80.87
Camarilla ₹85.44 ₹85.16 ₹84.89 ₹83.87 ₹84.34 ₹84.06 ₹83.79

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+15.87%

1 Week

-3.96%

1 Month

-3.08%

3 Months

-1.54%

6 Months

+3.15%

1 Year

+8.84%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹69.57

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.18%

Net margin 2.29% × asset turnover 0.76x × equity multiplier 4.7x

Company Overview

Sector

Healthcare

Market Cap

₹135 Cr

P/E (TTM)

17.1

ROE

7.79%

Book Value

₹54.6

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Bal Pharma Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 39/100. The strongest factor is Corporate Governance (90/100), while Financial Strength (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (2.07); low return on equity (7.79%). Strong 3-year EPS growth (33.9%).

TopFund Score — Fundamentals Quality

39/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

0

Growth

36

Valuation

60

Cash Flow

46

Corporate Governance

90

Momentum

40

Institutional Ownership

30

Business Quality

30

Risk & Volatility

52

Liquidity

39

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 27.5%
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 4.46% over past five years.
  • −Tax rate seems low
  • −Company has a low return on equity of 9.34% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper publication of unaudited Q2 and half-year 2026-27 financial results, following November 11 board meeting.

Bal Pharma reported Q2 FY27 results on 11 Nov 2026; standalone profit ₹152.71 lakh, no warrant utilization.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 93 82 95 74 74 73 82 66 74 88 84 89 90
Expenses + 85 74 85 68 66 65 74 60 68 78 74 81 81
Operating Profit 8 8 10 6 8 8 8 6 6 10 11 8 9
OPM % 8.32% 9.54% 10.14% 8.7% 10.44% 10.59% 9.33% 9.2% 7.74% 10.88% 12.58% 8.97% 9.63%
Other Income + 0 0 2 1 0 1 1 1 1 0 0 0 2
Interest 4 4 4 4 4 5 4 4 4 5 4 4 5
Depreciation 2 3 2 2 2 3 2 3 2 3 3 3 3
Profit before tax 2 1 6 1 1 1 3 0 1 2 3 1 2
Tax % 39.38% 33.07% 3.65% 58.06% 23.53% 7.14% -108.88% 0.0% 0.0% 0.0% -12.11% 0.0% 25.91%
Net Profit + 1 1 6 0 1 1 5 0 1 2 4 1 1
EPS in Rs 1 1 3 0 1 0 3 0 0 1 2 1 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 23 7 15 6 -20 -10 -13 -11 0 20 3 35 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 187 198 229 211 225 171 251 281 304 339 303 312 350
Expenses + 170 183 214 194 207 166 226 257 279 308 273 280 314
Operating Profit 17 15 15 17 18 5 25 24 25 31 30 32 37
OPM % 9.0% 7.0% 6.0% 8.0% 8.0% 2.9% 10.0% 9.0% 8.0% 9.0% 10.0% 10.0% 10.0%
Other Income + 1 1 3 2 1 2 1 5 1 3 2 2 2
Interest 7 6 8 9 13 13 12 11 12 15 17 17 18
Depreciation 7 7 6 7 6 8 10 9 9 10 10 11 12
Profit before tax 5 3 3 3 0 -14 4 9 5 9 5 6 8
Tax % 25.0% 90.0% 114.0% 87.0% -1,175.0% -5.0% -15.0% 38.0% 45.0% 18.0% -41.0% -7.0% —
Net Profit + 4 1 0 0 2 -13 5 6 3 7 7 6 8
EPS in Rs 3 1 1 2 3 -9 3 4 2 5 5 4 5
Dividend Payout % 35.0% 91.0% 81.0% 51.0% 37.0% 0.0% 31.0% 26.0% 61.0% 26.0% 26.0% 30.0% —
Sales growth 5 6 15 -8 6 -24 46 12 8 12 -11 3 19

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 42 42 48 51 52 38 39 44 48 56 62 66 71
Borrowings + 49 89 93 110 124 118 110 104 131 140 150 160 180
Other Liabilities + 59 67 78 86 71 68 76 98 116 108 108 134 142
Total Liabilities 164 211 233 260 261 238 240 261 311 320 336 376 409
Fixed Assets + 52 56 60 71 70 71 69 67 76 80 87 94 102
CWIP 1 4 2 0 4 3 0 2 0 0 3 7 2
Investments 0 0 0 0 0 0 0 0 0 7 2 2 3
Other Assets + 111 151 172 188 187 164 172 192 235 233 244 272 301
Total Assets 164 211 233 260 261 238 240 261 311 320 336 376 409
Equity Capital 13 13 14 14 14 14 15 15 16 16 16 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 15 -19 6 1 8 23 22 27 -2 23 20 31
Cash from Investing Activity + -5 -14 -8 -4 -8 -5 -6 -9 -22 -19 -15 -21
Cash from Financing Activity + -7 32 -6 4 0 -20 -17 -17 24 -1 -8 -10
Net Cash Flow 2 -1 -8 1 0 -2 0 0 0 3 -2 1
Free Cash Flow 9 -34 -2 -3 -1 18 19 18 -16 12 2 9
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 93 -125 52 11 57 465 91 117 -4 88 75 96

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 51.24% → 50.87%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 48.64% 48.64% 48.63% 49.01% 49.0% 49.01% 48.99% 48.91% 49.01% 49.01% 48.99% 48.87%
Promoters 51.24% 51.24% 51.24% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87%
FII 0.13% 0.13% 0.13% 0.13% 0.14% 0.14% 0.15% 0.23% 0.14% 0.14% 0.15% 0.28%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bal Pharma Ltd. (this stock) 135 17.1 1.58 7.79%
Natural Capsules Limited 144 — 0.66 -9.45%
Parnax Lab Ltd. 125 14.6 1.27 14.2%
Alpa Laboratories Ltd 109 52.0 0.59 8.38%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Vaishali Pharma Limited 95 21.4 1.33 5.83%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%

Which Mutual Funds Hold Bal Pharma Ltd.?

Frequently Asked Questions about Bal Pharma Ltd.

Community Sentiment

What are other investors saying about Bal Pharma Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.